Recent Publications

• Smith SM, Heer M, Wang Z, Huntoon CL, Zwart SR.
• Long-Duration Space Flight and Bed Rest Effects on Testosterone and Other Steroids.
• J Clin Endocrinol Metab. 2011 Nov 2. [Epub ahead of print]
• Graf S, Egert S, Heer M.
• Effects of whey protein supplements on metabolism: evidence from human intervention studies.
• Curr Opin Clin Nutr Metab Care. 14(6):569-80, 2011
• Baecker N, Frings-Meuthen P, Heer M, Mester J, Liphardt AM.
• Effects of vibration training on bone metabolism: results from a short-term bed rest study.
• Eur J Appl Physiol. 2011 Sep 6. [Epub ahead of print]
• Belavy DL, Bansmann PM, Böhme G, Frings-Meuthen P, Heer M, Rittweger J, Zange J, Felsenberg D.
• Changes in intervertebral disc morphology persist 5 mo after 21-day bed rest.
• J Appl Physiol. 111(5):1304-14, 2011 Epub 2011 Jul 28.
• Frings-Meuthen P, Buehlmeier J, Baecker N, Stehle P, Fimmers R, May F, Kluge G, Heer M.
• High sodium chloride intake exacerbates immobilization-induced bone resorption and protein losses.
• J Appl Physiol. 111(2):537-42, 2011 Epub 2011 May 19.
• Navasiolava NM, Pajot A, Gallois Y, Pastushkova LKh, Kulchitsky VA, Gauquelin-Koch G, Kozlovskaya IB, Heer M, Hand O, Larina IM, Custaud MA.
• NT-ProBNP levels, water and sodium homeostasis in healthy men: effects of 7 days of dry immersion.
• Eur J Appl Physiol. 111(9):2229-37, 2011 Epub 2011 Feb 16.
• Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H
• Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the randomized DIATOR trial
• PLOs.ONE 6:e17554
• Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, Woerle HJ
• Effect of Renal Impairment on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin
• Diabetes Obes Metab 13: 939–946, 2011
• Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L
• Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection
• Diabetes Technol. Ther., 13:435-442, 2011
• Pettis RJ, Hirsch L, Kapitza C, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L
• Microneedle-Based Intradermal Versus Subcutaneous Administration of Regular Human Insulin or Insulin Lispro: Pharmacokinetics and Postprandial Glycemic Excursions in Patients with Type 1 Diabetes
• Diabetes Technol. Ther., 13:443-450, 2011
• Jax T, Heise T, Nosek L, Gable J, Lim G, Calentine C
• Automated Near-Continuous Glucose Monitoring Measured in Plasma Using Mid-Infrared Spectroscopy
• J. Diabetes Sci. Technol., 5:345-352, 2011
• Heise T, Tack CJ, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R
• A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes. A randomized, controlled trial
• Diabetes Care, 34:669-674, 2011
• Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A
• Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide
• J. Clin. PPharmacol., 51:842-856, 2011
• Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R
• Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study
• J. Clin. Endocrinol. Metab., 95:5028-5036, 2010
• Arnolds, S., Rave, K., Hövelmann, U., Fischer, A., Sert-Langeron, C., Heise, T.
• Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
• Exp. Clin. Endocrinol. Diabetes., 118:662-664, 2010
• Arnolds S, Kuglin B, Kapitza C, Heise T
• How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
• Int. J. Clin. Pract., 64:1415-1424, 2010
• Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R
• Safety and tolerability of high doses of taspoglutide: a once weekly human GLP-1 analogue in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study
• Diabet. Med. 2010; 27:556-562.
• Arnolds, S., Dellweg, S., Clair, J., Dain, M.P., Nauck, M.A., Rave, K., Kapitza, C.
• Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) - a proof-of-concept study.
• Diabetes Care 33:1509–1515, 2010
• Heise,T., Mathieu,C., Hey-Hadavi,J., Strack,T., and Lawrence,D.
• Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents.
• Diabetes Technol. Ther. 12:135-141, 2010.
• Kapitza,C., Zijlstra,E., Heinemann,L., Castelli,M.C., Riley,G., and Heise,T.
• Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes.
• Diabetes Care, 33:1288-1290, 2010
• Kapitza,C., Hovelmann,U., Nosek,L., Kurth,H.J., Essenpreis,M., and Heinemann,L.
• Continuous Glucose Monitoring during Exercise in Patients with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion.
• J. Diabetes Sci. Technol. 4:123-131, 2010.
• Rave,K., Sidharta,P.N., Dingemanse,J., Heinemann,L., and Roggen,K.
• First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal test.
• Diabetes Technol. Ther. 12:117-123, 2010.

Home